Congrats to the team at Jnana Tx! Founding team includes our own founding CEO Stuart Schreiber. Jnana's story is a powerful example of the importance of understanding the mechanisms of human disease and finding the right clinical biomarkers. They're now a big step closer to reaching patients.
Jnana Therapeutics announced today that it has entered into an agreement to be acquired by Otsuka Pharmaceutical Co. By bringing together the strength of Jnana’s RAPID platform with Otsuka’s global capabilities and resources, the proposed transaction will further enable the development of novel therapies for under-addressed diseases, including JNT-517 for PKU. Upon completion of the acquisition later this year, Jnana will operate as a wholly owned subsidiary of Otsuka in Boston and continue its research and development. Read more: https://bit.ly/4ftndW9 #biotechnology #biopharma #acquisition